Principal Financial Group
MRNA icon

Principal Financial Group’s Moderna MRNA Stock Holding History

Principal Financial Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.7M Buy
387,718
+3,790
+1% +$177K 0.01% 938
2025
Q4 		$11.3M Buy
383,928
+10,874
+3% +$295K 0.01% 1237
2025
Q3 		$9.64M Buy
373,054
+1,442
+0.4% +$40.2K ﹤0.01% 1310
2025
Q2 		$10.3M Sell
371,612
-9
-0% -$237 0.01% 1253
2025
Q1 		$10.5M Sell
371,621
-1,863
-0.5% -$66.1K 0.01% 1227
2024
Q4 		$15.5M Sell
373,484
-5,967
-2% -$285K 0.01% 1024
2024
Q3 		$25.4M Buy
379,451
+15,218
+4% +$1.4M 0.01% 722
2024
Q2 		$43.3M Buy
364,233
+328
+0.1% +$41.5K 0.03% 509
2024
Q1 		$38.8M Buy
363,905
+2,948
+0.8% +$297K 0.02% 569
2023
Q4 		$35.9M Sell
360,957
-1,949
-0.5% -$164K 0.02% 561
2023
Q3 		$37.5M Buy
362,906
+742
+0.2% +$82.8K 0.03% 509
2023
Q2 		$44M Sell
362,164
-17,351
-5% -$2.31M 0.03% 467
2023
Q1 		$58.3M Buy
379,515
+5,614
+2% +$926K 0.04% 383
2022
Q4 		$67.2M Sell
373,901
-16,962
-4% -$2.77M 0.05% 312
2022
Q3 		$46.2M Sell
390,863
-18,924
-5% -$2.87M 0.04% 404
2022
Q2 		$58.5M Sell
409,787
-18,835
-4% -$2.69M 0.04% 350
2022
Q1 		$73.8M Sell
428,622
-468
-0.1% -$78.8K 0.05% 327
2021
Q4 		$109M Sell
429,090
-8,293
-2% -$2.42M 0.07% 249
2021
Q3 		$168M Buy
437,383
+402,212
+1,144% +$148M 0.11% 191
2021
Q2 		$8.27M Sell
35,171
-60,326
-63% -$10.8M 0.01% 1511
2021
Q1 		$12.5M Buy
95,497
+4,648
+5% +$674K 0.01% 1273
2020
Q4 		$9.49M Sell
90,849
-12,991
-13% -$1.31M 0.01% 1263
2020
Q3 		$7.35M Sell
103,840
-5,828
-5% -$406K 0.01% 1253
2020
Q2 		$7.04M Buy
109,668
+34,291
+45% +$1.88M 0.01% 1263
2020
Q1 		$2.26M Buy
75,377
+5,009
+7% +$115K ﹤0.01% 1561
2019
Q4 		$1.38M Buy
70,368
+19,482
+38% +$346K ﹤0.01% 1782
2019
Q3 		$810K Sell
50,886
-24
-0% -$355 ﹤0.01% 1857
2019
Q2 		$745K Buy
+50,910
New +$1.09M ﹤0.01% 1888

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Principal Financial Group's MRNA Position: Q1 2026 in Review

Principal Financial Group increased its Moderna (MRNA) stake by 0.99% in Q1 2026, buying an estimated $177K and bringing the position to 387,718 shares worth $19.7M. The position accounts for 0.01% of the portfolio, ranked #938.

Principal Financial Group first reported a position in MRNA in Q2 2019 and has held it in 28 quarters since. The position peaked at $168M in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Principal Financial Group held 387,718 shares of Moderna worth $19.7M as of Q1 2026.
  • Principal Financial Group bought 3,790 Moderna shares in Q1 2026, an estimated $177K.
  • Moderna made up 0.01% of Principal Financial Group's portfolio in Q1 2026, its #938 holding.
  • Principal Financial Group first reported a position in Moderna in Q2 2019 and has held it in 28 quarters since.
  • Principal Financial Group's Moderna position peaked at $168M in Q3 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Principal Financial Group's 13F filing for Q1 2026, filed 4 May 2026.